Nkarta (NKTX) Income from Continuing Operations (2019 - 2026)
Nkarta's quarterly Income from Continuing Operations came in at 28038000.0 in Q1 2026, up 12.89% year-on-year from 24835905.77 in Q1 2025, and down 1.35% quarter-over-quarter from 27665000.0 in Q4 2025.
Nkarta has reported Income from Continuing Operations for 8 years, with the latest figure at 28038000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 12.89% year-over-year to 28038000.0; the trailing twelve-month figure through Mar 2026 stood at 102353000.0 (up 8.24% YoY), and the FY2025 full-year result was 106503000.0, up 2.18% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 28038000.0, down from 27665000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 23216000.0 in Q2 2025, with the low at 33288000.0 in Q2 2023.
- Average Income from Continuing Operations over 5 years is 27901647.06, with a median of 27729000.0 recorded in 2023.
- Year-over-year, Income from Continuing Operations tumbled 40.68% in 2022 and rose 24.92% in 2024.
- Tracing NKTX's Income from Continuing Operations over 5 years: stood at 32093000.0 in 2022, then increased by 13.6% to 27729000.0 in 2023, then increased by 6.13% to 26029000.0 in 2024, then decreased by 6.29% to 27665000.0 in 2025, then retreated by 1.35% to 28038000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 28038000.0 (Q1 2026), 27665000.0 (Q4 2025), and 23434000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -28.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.04 Mn |
| Dec 31, 2025 | -27.67 Mn |
| Sep 30, 2025 | -23.43 Mn |
| Jun 30, 2025 | -23.22 Mn |
| Mar 31, 2025 | -32.19 Mn |
| Dec 31, 2024 | -26.03 Mn |
| Sep 30, 2024 | -28.34 Mn |
| Jun 30, 2024 | -24.99 Mn |
| Mar 31, 2024 | -29.52 Mn |
| Dec 31, 2023 | -27.73 Mn |
| Sep 30, 2023 | -25.68 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -30.85 Mn |
| Dec 31, 2022 | -32.09 Mn |
| Sep 30, 2022 | -28.36 Mn |
| Jun 30, 2022 | -26.93 Mn |
| Mar 31, 2022 | -25.99 Mn |
| Dec 31, 2021 | -22.81 Mn |
| Sep 30, 2021 | -22.35 Mn |
| Jun 30, 2021 | -21.53 Mn |
| Mar 31, 2021 | -19.37 Mn |
| Dec 31, 2020 | -18.04 Mn |
| Sep 30, 2020 | -13.54 Mn |
| Jun 30, 2020 | -10.33 Mn |
| Mar 31, 2020 | -9.28 Mn |
| Dec 31, 2019 | -8.40 Mn |
| Sep 30, 2019 | -5.91 Mn |
| Jun 30, 2019 | -4.65 Mn |